• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Jpn J Infect Dis . Antiviral susceptibilities of avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan

tetano

Editor, Senior Moderator
Jpn J Infect Dis


. 2021 Dec 28.
doi: 10.7883/yoken.JJID.2021.751. Online ahead of print.
Antiviral susceptibilities of avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan


Emi Takashita[SUP] 1 [/SUP], Hiroko Morita[SUP] 1 [/SUP], Shiho Nagata[SUP] 1 [/SUP], Masayuki Shirakura[SUP] 1 [/SUP], Seiichiro Fujisaki[SUP] 1 [/SUP], Hideka Miura[SUP] 1 [/SUP], Ikuyo Takayama[SUP] 1 [/SUP], Tomoko Arita[SUP] 1 [/SUP], Yasushi Suzuki[SUP] 1 [/SUP], Masaoki Yamaoka[SUP] 2 [/SUP], Taichiro Tanikawa[SUP] 3 [/SUP], Ryota Tsunekuni[SUP] 4 [/SUP], Junki Mine[SUP] 4 [/SUP], Saki Sakuma[SUP] 4 [/SUP], Yuko Uchida[SUP] 4 [/SUP], Akihiro Shibata[SUP] 5 [/SUP], Mari Iwanaka[SUP] 5 [/SUP], Noriko Kishida[SUP] 1 [/SUP], Kazuya Nakamura[SUP] 1 [/SUP], Tsutomu Kageyama[SUP] 1 [/SUP], Shinji Watanabe[SUP] 1 [/SUP], Hideki Hasegawa[SUP] 1 [/SUP], Influenza Virus Surveillance Group of Japan[SUP] 6 [/SUP]



Affiliations

Abstract

Circulation of avian influenza A viruses in poultry is a public health concern because these viruses may cause severe disease in humans and have the potential to become more transmissible among humans. Monitoring the susceptibility of these viruses to antivirals is important for influenza pandemic preparedness. However, information about their antiviral susceptibility is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: the M2 inhibitor amantadine; the neuraminidase inhibitors oseltamivir, peramivir, zanamivir, and laninamivir; and the RNA polymerase inhibitors baloxavir and favipiravir. Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess viral susceptibility to drugs revealed that these avian influenza A viruses are susceptible to neuraminidase inhibitors and RNA polymerase inhibitors. These results suggest that the neuraminidase inhibitors and the RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans.

Keywords: Avian influenza; RNA polymerase inhibitor; antiviral susceptibility; neuraminidase inhibitor.
 
Back
Top Bottom